Shionogi Inc v. Sandoz Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Shionogi Inc. (Delaware)
  • Defendant: Sandoz Inc. (Delaware)
  • Plaintiff's Counsel: FBT Gibbons LLP
• Case Identification: 2:26-cv-07063, D.N.J., 06/12/2026
• Venue Allegations: Plaintiff Shionogi Inc. alleges venue is proper in the District of New Jersey because Defendant Sandoz Inc. has a regular and established place of business in the state and has committed alleged acts of infringement in New Jersey.
• Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) seeking approval for a generic version of the drug RADICAVA ORS® constitutes an act of infringement of three patents related to pharmaceutical compositions and administration methods for edaravone.
• Technical Context: The technology concerns oral formulations of the drug edaravone, used to treat Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease, in a manner that avoids the drug's absorption being negatively affected by food consumption.
• Key Procedural History: This action was triggered by Sandoz's submission of ANDA No. 220086 with a Paragraph IV certification, asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by its proposed generic product. The complaint notes that Shionogi recently acquired the RADICAVA ORS® assets from Tanabe Pharma Corporation and that numerous related infringement actions against other generic drug manufacturers are pending in the same district.

Case Timeline

Date	Event
2020-11-12	Earliest Priority Date for '611, '769, and '469 Patents
2022-05-12	FDA Approval of RADICAVA ORS® (NDA No. 215446)
2024-03-28	FDA Grants Orphan Drug Exclusivity for RADICAVA ORS®
2025-11-25	U.S. Patent No. 12,478,611 Issues
2025-12-22	Shionogi Announces Agreement to Acquire RADICAVA ORS® Business
2026-01-20	U.S. Patent No. 12,527,769 Issues
2026-03-10	U.S. Patent No. 12,569,469 Issues
2026-04-01	Shionogi Completes Acquisition of RADICAVA ORS® Assets
2026-04-30	Sandoz Sends Paragraph IV Notice Letter to Shionogi
2026-06-12	Complaint for Patent Infringement Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,478,611 - Pharmaceutical composition for oral administration of edaravone and method of administering same

The Invention Explained

• Problem Addressed: The patent discloses that edaravone, a treatment for the oxidative stress disease ALS, was previously only available as an injectable agent '611 Patent, col. 1:56-61 While an oral formulation offers convenience, its absorption and resulting pharmacokinetics (PK) can be negatively and unpredictably impacted by food consumption, potentially reducing efficacy '611 Patent, col. 15:1-16:38
• The Patented Solution: The invention claims a method for administering an oral liquid formulation of edaravone by specifying minimum time intervals between consumption of a meal and administration of the drug '611 Patent, abstract The length of the required time interval is tied to the type of meal consumed (e.g., 8 hours for a high-fat meal, 4 hours for a standard meal, 2 hours for a light meal), with the goal of achieving "the same pharmacokinetics" as if the drug were administered in a fasted state '611 Patent, col. 2:1-22
• Technical Importance: This dosing regimen allows ALS patients to benefit from a convenient oral formulation of edaravone without the burden of intravenous injections, while ensuring predictable and effective drug absorption that is not compromised by food intake Compl. ¶11 Compl. ¶12

Key Claims at a Glance

• The complaint asserts at least Independent Claim 1 of the '611 patent Compl. ¶40
• The essential elements of Independent Claim 1 are:
  • A method of treating amyotrophic lateral sclerosis.
  • The method comprises orally or intragastrically administering a liquid pharmaceutical composition containing edaravone.
  • The administration occurs after a specific "first time interval" following a meal, where the interval is defined as 8 hours for a high-fat meal, 4 hours for a standard meal, or 2 hours for a light meal.
  • This time interval achieves the "same pharmacokinetics" (including Cmax and AUC) as administration under a fasting condition.
  • The dose of edaravone administered is between 90 to 120 mg.
• The complaint alleges infringement of one or more claims, including at least Claim 1, suggesting dependent claims may be asserted later Compl. ¶40 Compl. ¶41

U.S. Patent No. 12,527,769 - Pharmaceutical composition for oral administration of edaravone and method of administering same

The Invention Explained

• Problem Addressed: As with the '611 patent, the '769 patent addresses the problem of food consumption altering the bioavailability of orally administered edaravone, making its therapeutic effect less predictable '769 Patent, col. 15:58-16:2
• The Patented Solution: The '769 patent claims a method for administering a suspension of edaravone with specific timing relative to meals. It quantifies the desired PK outcome by requiring that any resulting decrease in maximum plasma concentration (Cmax) be less than 20% and any decrease in the area under the curve (AUC) be less than 10% compared to administration in a fasted state '769 Patent, claim 1
• Technical Importance: This method provides a more concrete, quantifiable standard for bioequivalence compared to the '611 patent, specifically defining the acceptable impact of food on the PK profile for an oral edaravone suspension, thereby ensuring therapeutic consistency.

Key Claims at a Glance

• The complaint asserts at least Independent Claim 1 of the '769 patent Compl. ¶51
• The essential elements of Independent Claim 1 are:
  • A method of treating amyotrophic lateral sclerosis.
  • The method comprises orally or intragastrically administering a liquid pharmaceutical composition that is a suspension containing edaravone.
  • The administration occurs after a specific "first time interval" following a meal (8 hours for high-fat, 4 hours for low-fat, 2 hours for caloric supplement).
  • This method results in a decrease in Cmax of less than 20% and/or a decrease in AUC of less than 10%, relative to administration in a fasted state.
• The complaint reserves the right to assert additional claims Compl. ¶51

U.S. Patent No. 12,569,469 - Pharmaceutical composition for oral administration of edaravone and method of administering same

Technology Synopsis

• This patent addresses the same problem of food-drug interaction with oral edaravone '469 Patent, col. 15:55-16:2 The claimed method includes the pre-administration time intervals based on meal type, but adds a further limitation: a "second time interval" after drug administration, during which the patient must wait before consuming the next meal, such as 1 hour or longer '469 Patent, claim 1 '469 Patent, claim 3

Asserted Claims

• At least Independent Claim 1 Compl. ¶62

Accused Features

• The administration of Sandoz's proposed generic edaravone suspension is alleged to meet the claimed limitations, including the pre- and post-administration waiting periods Compl. ¶¶62-63

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant Sandoz's proposed generic edaravone oral suspension, which is the subject of ANDA No. 220086 Compl. ¶¶2 Compl. ¶35

Functionality and Market Context

• The product is an oral suspension of edaravone formulated at a dose of 105 mg/5 mL Compl. ¶33 It is intended to be a generic equivalent to Plaintiff's RADICAVA ORS® product for the treatment of ALS Compl. ¶34 Compl. ¶35
• The complaint alleges that RADICAVA ORS® is a major contribution to patient care because it provides a clinically superior oral administration option compared to the prior intravenous formulation, reducing the burden on patients Compl. ¶12 Sandoz's generic product would compete in this market Compl. ¶19 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that Sandoz's submission of ANDA No. 220086 constitutes an act of infringement under 35 U.S.C. § 271(e)(2) Compl. ¶42 Compl. ¶53 Compl. ¶64 The infringement theory is centered on induced infringement, alleging that Sandoz's proposed product labeling will instruct physicians and patients to administer the drug in a manner that directly infringes the asserted method claims Compl. ¶41 Compl. ¶52 Compl. ¶63

U.S. Patent No. 12,478,611 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating amyotrophic lateral sclerosis, comprising: orally or intragastrically administering, to a subject in need thereof, a liquid pharmaceutical composition comprising edaravone	Plaintiff alleges Sandoz's proposed product is an oral edaravone suspension for the treatment of ALS, and that its label will instruct administration.	¶33; ¶35; ¶41	col. 11:11-15; col. 33:20-27
with a first time interval from a consumption of a meal...such that the first time interval achieves the same pharmacokinetics as administration...under a fasting condition...and that the same pharmacokinetics includes Cmax and AUC,	Plaintiff alleges Sandoz's proposed label instructs administration in accordance with the claimed methods, thereby achieving the claimed pharmacokinetic result.	¶41	col. 33:27-38
wherein the liquid pharmaceutical composition is administered...such that a dose of edaravone per administration is in a range of 90 to 120 mg,	Plaintiff alleges Sandoz's product is administered at a dose of 105 mg, which falls within the claimed range.	¶33	col. 33:39-42
the first time interval for the consumption of a high-fat meal...is 8 hours before the administration..., the first time interval for the consumption of a standard meal...is 4 hours before the administration..., and the first time interval for the consumption of a light meal...is 2 hours before the administration...	Plaintiff alleges Sandoz's proposed label will instruct users to follow the specific meal-based timing intervals claimed in the patent.	¶41	col. 33:43-51

U.S. Patent No. 12,527,769 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating amyotrophic lateral sclerosis, comprising: orally or intragastrically administering, to a subject in need thereof, a liquid pharmaceutical composition...wherein the liquid pharmaceutical composition is a suspension comprising the edaravone,	Plaintiff alleges Sandoz's product is a proposed oral edaravone suspension for treating ALS.	¶33; ¶35; ¶52	col. 5:1-3; col. 43:20-26
the first time interval for the consumption of a high-fat meal...is 8 hours before...; the first time interval for the consumption of a low-fat meal...is 4 hours before...; or the first time interval for the consumption of a caloric supplement...is 2 hours before...	Plaintiff alleges Sandoz's proposed label will instruct users to follow the specific meal-based timing intervals.	¶52	col. 44:49-45:4
such that a decrease in Cmax is less than 20% with respect to Cmax in a same time range in fasting...and/or that a decrease in AUC is less than 10% with respect to AUC in a same time range in fasting...	Plaintiff alleges Sandoz's proposed product performs substantially the same function to obtain the same result, and that any differences are insubstantial, asserting both literal infringement and infringement under the doctrine of equivalents.	¶51	col. 45:5-11

Identified Points of Contention

• Evidentiary Questions: As the complaint does not include the proposed label, a central question will be whether the label for Sandoz's ANDA product actually instructs the specific, meal-dependent timing regimens required by the claims.
• Scope Questions: For the '611 patent, the meaning of "same pharmacokinetics" will be a key dispute. For the '769 patent, a key question will be whether Sandoz's product, when administered as instructed, actually meets the quantitative criteria for Cmax (<20% decrease) and AUC (<10% decrease) relative to a fasted state, or if there is a technical mismatch.

V. Key Claim Terms for Construction

• The Term: "same pharmacokinetics" (from Claim 1 of the '611 patent).
• Context and Importance: This term is the central performance requirement of the claimed method in the '611 patent. Its definition is critical because it sets the standard for determining whether the specified waiting periods successfully "avoid effects of meal consumption" '611 Patent, col. 5:50-54 Practitioners may focus on this term because it is potentially indefinite and its interpretation will dictate the scope of the claim and the evidence required to prove infringement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification states that "'the same pharmacokinetics' means, for example, that the target pharmacokinetics is completely identical or in a range not significantly different" '611 Patent, col. 6:3-6 This language may support an argument that absolute identity is not required.
  • Evidence for a Narrower Interpretation: The specification provides a specific example of what "same pharmacokinetics" means, referencing the common bioequivalence standard where "a least squares mean ratio and its 90% confidence interval are in the range of 0.8 to 1.25" '611 Patent, col. 6:15-19 A defendant may argue this example defines the required scope. The existence of the '769 patent, which recites specific percentage decreases, may also be used to argue that "same pharmacokinetics" implies a distinct, and possibly stricter, standard.

VI. Other Allegations

Indirect Infringement

The complaint explicitly alleges active inducement of infringement under 35 U.S.C. § 271(b) Compl. ¶41 Compl. ¶52 Compl. ¶63 The allegations are based on Sandoz's proposed product labeling, which Plaintiff claims will instruct and encourage physicians, patients, and healthcare providers to administer the generic product in a manner that directly infringes the patented methods.

Willful Infringement

The complaint alleges that Sandoz was aware of the patents-in-suit prior to amending its ANDA to include a Paragraph IV certification Compl. ¶45 Compl. ¶56 Compl. ¶67 It further alleges that Sandoz proceeded "despite an objectively high likelihood that its submission constituted infringement of a valid patent, and this risk was either known to Sandoz or so obvious that it should have been known," which tracks the standard for willful infringement Compl. ¶45 Compl. ¶56 Compl. ¶67

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of claim construction: How will the court define "same pharmacokinetics" in the '611 patent? The resolution of this question will determine whether a general similarity to a fasted state is sufficient for infringement, or if strict, quantitative bioequivalence metrics are required.
• A key evidentiary question will be one of instructed use: What are the precise administration instructions in Sandoz's ANDA and proposed label? The case will likely turn on whether these instructions direct, or merely permit, administration according to the patented meal-timing methods, which is central to the claim of induced infringement.
• A central technical question will be one of functional performance: Does Sandoz's proposed oral suspension, when used as instructed, actually achieve the pharmacokinetic outcomes required by the claims? Specifically, does its absorption profile meet the quantitative Cmax and AUC criteria of the '769 patent, or is there a functional mismatch that would preclude a finding of literal infringement?